Table 3.
Baseline characteristics according to the FDA/EC label and VICTORIA inclusion criteria
| Characteristics | FDA/EC label | VICTORIA inclusion criteria |
|---|---|---|
| (N = 2861) | (N = 1748) | |
| Male (%) | 58.4% | 56.2% |
| Age (years) | 67 ± 15 | 69 ± 14 |
| BMI (kg/m2) | 23.2 ± 3.8 | 23.1 ± 3.8 |
| Ischaemic origin (%) | 40.9% | 46.2% |
| Diabetes (%) | 35.0% | 39.1% |
| Hypertension (%) | 54.9% | 61.8% |
| COPD (%) | 10.5% | 10.7% |
| Atrial fibrillation (%) | 30.4% | 27.8% |
| Systolic blood pressure (mmHg) | 113 ± 19 | 120 ± 16 |
| Diastolic blood pressure (mmHg) | 67 ± 13 | 70 ± 11 |
| Heart rate (b.p.m.) | 81 ± 17 | 81 ± 17 |
| LVEF (%) | 28.6 ± 8.7 | 28.9 ± 8.7 |
| eGFR (mL/min/1.73 m2) | 71.4 ± 32.0 | 67.4 ± 32.0 |
| >60 (%) | 61.8% | 55.8% |
| >30 to ≤60 (%) | 31.1% | 34.7% |
| ≤30 (%) | 7.1% | 9.6% |
| Haemoglobin (g/dL) | 12.9 ± 2.2 | 12.6 ± 2.2 |
| Sodium (mmol/L) | 138.4 ± 3.8 | 138.7 ± 3.7 |
| Potassium (mmol/L) | 4.5 ± 0.5 | 4.6 ± 0.6 |
| BNP (pg/mL) | 1020 [523–1670] | 1010 [553–1615] |
| NT‐proBNP (pg/mL) | 3476 [1848–7883] | 3334 [1862–7584] |
| Heart failure treatments | ||
| ACEi/ARB/ARNI (%) | 77.8% | 76.0% |
| BB (%) | 58.3% | 57.5% |
| MRA (%) | 53.3% | 49.9% |
EC, European Commission; FDA, Food and Drug Administration. Other abbreviations in Table 1 .